AdaptHealth (AHCO)
(Delayed Data from NSDQ)
$9.48 USD
+0.40 (4.41%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $9.42 -0.06 (-0.63%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
AHCO 9.48 +0.40(4.41%)
Will AHCO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AHCO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AHCO
AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
AHCO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
AHCO or PBH: Which Is the Better Value Stock Right Now?
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
Other News for AHCO
AdaptHealth Corp. to Participate in the Canaccord Genuity 44th Annual Growth Conference
AdaptHealth (AHCO) Receives a Buy from Truist Financial
Buy Rating Affirmed for AdaptHealth on Strong Q2 Performance and Strategic Growth Initiatives
AdaptHealth Analysis: Hold Rating Amidst Revised Guidance and Financial Headwinds
AHCO Stock Earnings: AdaptHealth Beats EPS, Beats Revenue for Q2 2024